Pre-Made Epoetin Alfa biosimilar, Recombinant Protein: Recombinant EPO(erythropoietin) therapeutic protein targeting EPOR for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Epoetin Alfa biosimilar, Recombinant Protein: Recombinant EPO(erythropoietin) therapeutic protein targeting EPOR is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Epoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology.[3] Authorised by the European Medicines Agency on 28 August 27, it stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.
Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures
| Products Name (INN Index) | Pre-Made Epoetin Alfa biosimilar, Recombinant Protein: Recombinant EPO(erythropoietin) therapeutic protein targeting EPOR Pre-made [INN Name] biosimilar, [Format] targeting [Target1/Target2]), recom |
|---|---|
| INN Name | epoetin alfa |
| Target | EPOR |
| Format | Recombinant Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | EPO |
| VD LC | EPO |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Centocor?Ortho Biotech?Products?LP (Raritan NJ USA) / Amgen (Thousand Oaks CA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | EPOR |
| Package |
